A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients

[1]  M. Suntharalingam,et al.  Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial , 2017, JAMA oncology.

[2]  J. Trojan,et al.  Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial , 2017, Zeitschrift für Gastroenterologie.

[3]  H. Hawle,et al.  Intergroup phase III trial of neo-adjuvant chemotherapy, followed by chemoradiation and surgery with and without cetuximab in locally advanced esophageal carcinoma: First results from the SAKK 75/08 trial. , 2017 .

[4]  J. Trojan,et al.  Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. , 2017 .

[5]  C. Hurt,et al.  Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/− cetuximab in oesophageal cancer , 2017, British Journal of Cancer.

[6]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[7]  E. Steyerberg,et al.  Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. , 2015, The Lancet. Oncology.

[8]  H. Grabsch,et al.  LBA-03Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma: results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072) , 2015 .

[9]  Sue S Yom,et al.  Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D. Richel,et al.  Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. Thall,et al.  A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  A. Wotherspoon,et al.  Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial , 2013, The Lancet. Oncology.

[13]  Galina Kurteva,et al.  Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. , 2013, The Lancet. Oncology.

[14]  Dong-Bin Wang,et al.  Neoadjuvant Chemoradiotherapy Could Improve Survival Outcomes for Esophageal Carcinoma: A Meta-Analysis , 2012, Digestive Diseases and Sciences.

[15]  E W Steyerberg,et al.  Preoperative chemoradiotherapy for esophageal or junctional cancer. , 2012, The New England journal of medicine.

[16]  Y. Yatabe,et al.  Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer. , 2011, Anticancer research.

[17]  V. Gebski,et al.  Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. , 2011, The Lancet. Oncology.

[18]  T. Ruhstaller,et al.  Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  H. Baba,et al.  Induction Chemotherapy with Docetaxel/Cisplatin/5-Fluorouracil for Patients with Node-Positive Esophageal Cancer , 2011, Digestion.

[20]  Jordi Giralt,et al.  Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. , 2010, The Lancet. Oncology.

[21]  W. Allum,et al.  Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Edward S. Kim,et al.  A phase 2 study of cetuximab in combination with docetaxel in chemotherapy‐refractory/resistant patients with advanced nonsmall cell lung cancer , 2009, Cancer.

[23]  M. Stuschke,et al.  Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Haddad,et al.  Induction chemotherapy in locally advanced head and neck cancer: a new standard of care? , 2008, Hematology/oncology clinics of North America.

[25]  C. Bokemeyer,et al.  Platinum-based chemotherapy plus cetuximab in head and neck cancer. , 2008, The New England journal of medicine.

[26]  D. Sugarbaker,et al.  Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  T. Gorlia,et al.  Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. , 2007, The New England journal of medicine.

[28]  J. Ajani,et al.  Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas , 2007, Cancer.

[29]  J. Ajani,et al.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  C. V. D. van de Velde,et al.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.

[31]  J. Bourhis,et al.  Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  M. Goldwasser,et al.  Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. Rigas,et al.  Docetaxel in the treatment of esophageal cancer. , 2005, Seminars in oncology.

[34]  Kazuhiro Yoshida,et al.  Expression of growth factors and their receptors in human esophageal carcinomas: regulation of expression by epidermal growth factor and transforming growth factor α , 2005, Journal of Cancer Research and Clinical Oncology.

[35]  I. Hyodo,et al.  A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  Tsung-Teh Wu,et al.  Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  R. Nicholson,et al.  EGFR and cancer prognosis. , 2001, European journal of cancer.

[38]  Shohei Koyama,et al.  Expression of epidermal growth factor receptor and CD44 splicing variants sharing exons 6 and 9 on gastric and esophageal carcinomas: a two-color flow-cytometric analysis , 1999, Journal of Cancer Research and Clinical Oncology.

[39]  B. Kavanagh,et al.  Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation , 1997, Oncogene.

[40]  T. Walsh,et al.  A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. , 1996, The New England journal of medicine.